Jackson Square Partners LLC Has $2.95 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Jackson Square Partners LLC lessened its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 14,996 shares of the medical research company’s stock after selling 746 shares during the quarter. Jackson Square Partners LLC’s holdings in IQVIA were worth $2,947,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Avior Wealth Management LLC increased its stake in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the period. Synergy Asset Management LLC bought a new stake in IQVIA during the 4th quarter worth approximately $33,000. Lee Danner & Bass Inc. acquired a new position in IQVIA in the 4th quarter valued at approximately $44,000. Zions Bancorporation N.A. raised its stake in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 85 shares during the last quarter. Finally, Versant Capital Management Inc lifted its holdings in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after purchasing an additional 93 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 0.2 %

Shares of NYSE:IQV opened at $186.35 on Tuesday. The firm has a market cap of $32.86 billion, a P/E ratio of 24.85, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $254.54. The business’s 50 day simple moving average is $194.58 and its two-hundred day simple moving average is $207.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IQV. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Robert W. Baird cut their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Finally, Stifel Nicolaus dropped their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.